Your request to link to rcsb for BDBM130909

• 2BUJ: crystal structure of the human serine-threonine kinase 16 in complex with staurosporine
• 2PZY: structure of mk2 complexed with compound 76 (10.1016/J.BMCL.2007.05.101 )
• 5T5T: ampk bound to allosteric activator (10.1124/JPET.116.237925 )
• 3FME: crystal structure of human mitogen-activated protein kinase kinase 6 (mek6) activated mutant (s207d, t211d)
• 4U9A: sulphur anomalous crystal structure of asymmetric irak4 dimer (10.1016/J.MOLCEL.2014.08.006 )
• 4U97: crystal structure of asymmetric irak4 dimer (10.1016/J.MOLCEL.2014.08.006 )
• 5NG2: structure of rip2k(d146n) with bound staurosporine (10.1371/JOURNAL.PONE.0177161 )
• 1NXK: crystal structure of staurosporine bound to map kap kinase 2 (10.1016/S0969-2126(03)00092-3 )
• 4BF2: crystal structures of ask1-inhibitor complexes (10.1002/PRO.2298 )
• 1AQ1: human cyclin dependent kinase 2 complexed with the inhibitor staurosporine (10.1038/NSB1097-796 )
• 1XBC: crystal structure of the syk tyrosine kinase domain with staurosporin (10.1074/JBC.M409792200 )
• 5UFU: structure of ampk bound to activator (10.1016/J.CMET.2017.04.010 )
• 5E8W: tgf-beta receptor type 1 kinase domain (t204d) in complex with staurosporine (10.1107/S2059798316003624 )
• 1WVY: crystal structures of kinase domain of dap kinase in complex with small molecular inhibitors
• 2HW7: crystal structure of mnk2-d228g in complex with staurosporine (10.1038/SJ.EMBOJ.7601285 )
• 5E8X: tgf-beta receptor type 1 kinase domain (t204d,i211v,y249f,s280t, y282f,s287n,a350c,l352f) in complex with staurosporine (10.1107/S2059798316003624 )
• 6B2E: structure of full length human ampk (a2b2g1) in complex with a small molecule activator sc4. (10.1016/J.CHEMBIOL.2018.03.008 )
• 5EZV: x-ray crystal structure of amp-activated protein kinase alpha-2/alpha- 1 rim chimaera (alpha-2(1-347)/alpha-1(349-401)/alpha-2(397-end) beta-1 gamma-1) co-crystallized with c2 (5-(5-hydroxyl-isoxazol-3- yl)-furan-2-phosphonic acid) (10.1038/NCOMMS10912 )
• 1BYG: kinase domain of human c-terminal src kinase (csk) in complex with inhibitor staurosporine (10.1006/JMBI.1998.2369 )
• 3A62: crystal structure of phosphorylated p70s6k1 (10.1074/JBC.M109.040667 )
• 3A60: crystal structure of unphosphorylated p70s6k1 (form i) (10.1074/JBC.M109.040667 )
• 3A61: crystal structure of unphosphorylated p70s6k1 (form ii) (10.1074/JBC.M109.040667 )
• 5VED: pak4 kinase domain in complex with staurosporine (10.1016/J.BBAPAP.2017.10.004 )
• 6E4W: structure of ampk bound to activator (10.1021/ACS.JMEDCHEM.8B00807 )
• 6E4U: structure of ampk bound to activator (10.1021/ACS.JMEDCHEM.8B00807 )
• 6E4T: structure of ampk bound to activator (10.1021/ACS.JMEDCHEM.8B00807 )
• 1NVR: the complex structure of checkpoint kinase chk1/staurosporine (10.1074/JBC.M201233200 )
• 1OKY: structure of human pdk1 kinase domain in complex with staurosporine (10.1042/BJ20031119 )
• 6B1U: structure of full-length human ampk (a2b1g1) in complex with a small molecule activator sc4 (10.1016/J.CHEMBIOL.2018.03.008 )
• 3LCS: crystal structure of the anaplastic lymphoma kinase catalytic domain (10.1042/BJ20100609 )
• 3S95: crystal structure of the human limk1 kinase domain in complex with staurosporine
• 2GCD: tao2 kinase domain-staurosporine structure
• 3CKX: crystal structure of sterile 20-like kinase 3 (mst3, stk24) in complex with staurosporine
• 3P86: crystal structure of ctr1 kinase domain mutant d676n in complex with staurosporine (10.1016/J.JMB.2011.11.046 )
• 4ERW: cdk2 in complex with staurosporine (10.1002/CBIC.201200316 )
• 5ISO: structure of full length human ampk (non-phosphorylated at t-loop) in complex with a small molecule activator, a benzimidazole derivative (991)
• 4EZ7: cdk2 in complex with staurosporine and 2 molecules of 8-anilino-1- naphthalene sulfonic acid (10.1002/CBIC.201200316 )
• 4RLO: human p70s6k1 with ruthenium-based inhibitor em5 (10.1021/JM5011868 )
• 2OIC: crystal structure of irak4 kinase domain complexed with staurosporine
• 3ZEW: crystal structure of ephb4 in complex with staurosporine (10.1002/PRO.2445 )
• 2CLQ: structure of mitogen-activated protein kinase kinase kinase 5 (10.1016/J.STR.2007.08.011 )
• 5WNL: crystal structure of murine receptor-interacting protein 4 (ripk4) d143n bound to staurosporine (10.1016/J.STR.2018.04.002 )
• 5LOH: kinase domain of human greatwall (10.18632/ONCOTARGET.11511 )
• 1STC: camp-dependent protein kinase, alpha-catalytic subunit in complex with staurosporine (10.1016/S0969-2126(97)00310-9 )
• 1YHS: crystal structure of pim-1 bound to staurosporine (10.1074/JBC.M413155200 )
• 1E8Z: structure determinants of phosphoinositide 3-kinase inhibition by wortmannin, ly294002, quercetin, myricetin and staurosporine (10.1016/S1097-2765(05)00089-4 )
• 1U59: crystal structure of the zap-70 kinase domain in complex with staurosporine (10.1074/JBC.M407096200 )
• 4FR4: crystal structure of human serine/threonine-protein kinase 32a (yank1)
• 4CFE: structure of full length human ampk in complex with a small molecule activator, a benzimidazole derivative (991) (10.1038/NCOMMS4017 )
• 4CFF: structure of full length human ampk in complex with a small molecule activator, a thienopyridone derivative (a-769662) (10.1038/NCOMMS4017 )
• 4CFH: structure of an active form of mammalian ampk (10.1038/NATURE09932 )
• 3BKB: crystal structure of human feline sarcoma viral oncogene homologue (v- fes) (10.1016/J.CELL.2008.07.047 )
• 7NVQ: aerosol-soaked human cdk2 crystals with staurosporine (10.1107/S1600576721003551 )
• 3CBL: crystal structure of human feline sarcoma viral oncogene homologue (v- fes) in complex with staurosporine and a consensus peptide (10.1016/J.CELL.2008.07.047 )
• 1Q3D: gsk-3 beta complexed with staurosporine (10.1016/J.JMB.2003.08.031 )
• 4QFG: structure of ampk in complex with staurosporine inhibitor and in the absence of a synthetic activator (10.1016/J.STR.2014.06.009 )
• 4QFS: structure of ampk in complex with br2-a769662core activator and staurosporine inhibitor (10.1016/J.STR.2014.06.009 )
• 4QFR: structure of ampk in complex with cl-a769662 activator and staurosporine inhibitor (10.1016/J.STR.2014.06.009 )
• 1QPD: structural analysis of the lymphocyte-specific kinase lck in complex with non-selective and src family selective kinase inhibitors (10.1016/S0969-2126(99)80086-0 )
• 1QPJ: crystal structure of the lymphocyte-specific kinase lck in complex with staurosporine. (10.1016/S0969-2126(99)80086-0 )
• 3PPZ: crystal structure of ctr1 kinase domain in complex with staurosporine (10.1016/J.JMB.2011.11.046 )
• 1XJD: crystal structure of pkc-theta complexed with staurosporine at 2a resolution (10.1074/JBC.M409216200 )
• 4MVF: crystal structure of plasmodium falciparum cdpk2 complexed with inhibitor staurosporine
• 4YZC: crystal structure of pire1alpha in complex with staurosporine (10.1124/MOL.115.100917 )
• 2NRY: crystal structure of irak-4 (10.1016/J.STR.2006.11.001 )
• 3HMO: crystal structure of human mps1 catalytic domain in complex with the inhibitor staurosporine (10.1021/BI901970C )
• 4C34: pka-s6k1 chimera with staurosporine bound (10.18632/ONCOTARGET.1255 )
• 1SNU: crystal structure of the unphosphorylated interleukin-2 tyrosine kinase catalytic domain (10.1074/JBC.M400031200 )
• 5OOR: structure of chk1 10-pt. mutant complex with staurosporine (10.1021/ACS.JMEDCHEM.7B01186 )
• 2Z7R: crystal structure of the n-terminal kinase domain of human rsk1 bound to staurosporine (10.1110/PS.073123707 )
• 3D7T: structural basis for the recognition of c-src by its inactivator csk (10.1016/J.CELL.2008.05.051 )
• 2DQ7: crystal structure of fyn kinase domain complexed with staurosporine (10.1016/J.BBRC.2006.05.212 )
• 3A4O: lyn kinase domain (10.1016/J.BMCL.2009.10.038 )
• 4QMY: mst3 in complex with staurosporine (10.1002/CMDC.201600115 )
• 1SM2: crystal structure of the phosphorylated interleukin-2 tyrosine kinase catalytic domain (10.1074/JBC.M400031200 )
• 2YN8: ephb4 kinase domain inhibitor complex (10.1093/PROTEIN/GZT032 )
• 5E8Y: tgf-beta receptor type 2 kinase domain (e431a,r433a,e485a,k488a,r493a, r495a) in complex with staurosporine (10.1107/S2059798316003624 )
• 5KQ5: ampk bound to allosteric activator (10.1021/ACS.JMEDCHEM.6B00866 )
• 6C9J: amp-activated protein kinase bound to pharmacological activator r734 (10.1074/JBC.RA118.004883 )
• 6C9H: non-phosphorylated amp-activated protein kinase bound to pharmacological activator r734 (10.1074/JBC.RA118.004883 )
• 6C9F: amp-activated protein kinase bound to pharmacological activator r734 (10.1074/JBC.RA118.004883 )
• 6C9G: amp-activated protein kinase bound to pharmacological activator r739 (10.1074/JBC.RA118.004883 )
• 4RER: crystal structure of the phosphorylated human alpha1 beta2 gamma1 holo-ampk complex bound to amp and cyclodextrin (10.1038/CR.2014.150 )
• 3CD3: crystal structure of phosphorylated human feline sarcoma viral oncogene homologue (v-fes) in complex with staurosporine and a consensus peptide (10.1016/J.CELL.2008.07.047 )
• 4REW: crystal structure of the non-phosphorylated human alpha1 beta2 gamma1 holo-ampk complex (10.1038/CR.2014.150 )
• 7AKO: crystal structure of chk1 kinase domain in complex with a claspin phosphopeptide (10.1016/J.STR.2021.03.007 )